APA
Click to copy
Ali, F. S., Tabano, D., Borkar, D. S., Leng, T., Garmo, V., Ahmed, A., … Singh, R. P. (2025). Early Outcomes After Initiation of Faricimab for Neovascular Age-Related Macular Degeneration. Ophthalmic Surgery Lasers and Imaging Retina.
Chicago/Turabian
Click to copy
Ali, Ferhina S, David Tabano, Durga S. Borkar, Theodore Leng, Vincent Garmo, Ayesha Ahmed, Rachel Myers, Jacqueline K. Shaia, Giulio Barteselli, and Rishi P. Singh. “Early Outcomes After Initiation of Faricimab for Neovascular Age-Related Macular Degeneration.” Ophthalmic Surgery Lasers and Imaging Retina (2025).
MLA
Click to copy
Ali, Ferhina S., et al. “Early Outcomes After Initiation of Faricimab for Neovascular Age-Related Macular Degeneration.” Ophthalmic Surgery Lasers and Imaging Retina, 2025.
BibTeX Click to copy
@article{ferhina2025a,
title = {Early Outcomes After Initiation of Faricimab for Neovascular Age-Related Macular Degeneration.},
year = {2025},
journal = {Ophthalmic Surgery Lasers and Imaging Retina},
author = {Ali, Ferhina S and Tabano, David and Borkar, Durga S. and Leng, Theodore and Garmo, Vincent and Ahmed, Ayesha and Myers, Rachel and Shaia, Jacqueline K. and Barteselli, Giulio and Singh, Rishi P.}
}
BACKGROUND AND OBJECTIVE This study assessed treatment patterns and early outcomes among patients with neovascular age-related macular degeneration (nAMD) initiating faricimab in routine clinical practice in the United States.
PATIENTS AND METHODS FARETINA-AMD is a retrospective study among patients with nAMD initiating faricimab from February 2022 to June 2023 identified from the US IRIS® Registry.
RESULTS Included were 21,508 patients previously treated with anti-vascular endothelial growth factor (anti-VEGF) (25,784 eyes) and 1,836 treatment-naïve patients (1,982 eyes) with nAMD. Among previously treated eyes, visual acuity remained stable with faricimab. In treatment-naïve eyes, mean ± SD visual acuity improved from 56.7 ± 24.1 letters at index to 61.4 ± 22.3 after faricimab injection 4 (P < 0.01). Mean ± SD central subfield thickness improved from 315.2 ± 80.0 (index) to 264.9 ± 60.1 μm (injection 4) in treatment-naïve eyes and 296.2 ± 95.5 to 273.0 ± 81.4 μm in previously treated eyes (both P < 0.01).
CONCLUSIONS Among patients with nAMD receiving faricimab, visual acuity improved in treatment-naïve eyes, and both previously treated and treatment-naïve eyes experienced anatomical improvement. [Ophthalmic Surg Lasers Imaging Retina 2025;56:XX-XX.].